ReviewCancers2022
Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Prediction of Contralateral Lymph Node Involvement during Extended Pelvic Lymph Node Dissection for Clinically Unilateral Prostate Cancer.Annals of surgical oncology · 2026Article
- Pelvic lymph node management in prostate cancer: a narrative review.Prostate international · 2025Review
- Skip metastasis of prostate adenocarcinoma to mediastinal and hilar lymph nodes: a rare case and diagnostic challenge.Quantitative imaging in medicine and surgery · 2025Article
- Optimization of Extended Pelvic Lymph Node Dissection Side for Prostate Cancer.Annals of surgical oncology · 2024Article
- ASO Author Reflections: Optimization of Extended Pelvic Lymph Node Dissection Side for Prostate Cancer.Annals of surgical oncology · 2024Article
- Current status and therapeutic value of extended pelvic lymph node dissection during radical prostatectomy for prostate cancer.Prostate international · 2024Review
- Comparison of oncological outcomes between extended and no pelvic lymph node dissection in patients with high- or very high-risk prostate cancer: a multi-institutional study.Prostate international · 2024Article
- Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.Annals of surgical oncology · 2024Article
- ASO Author Reflections: Treatment Choice for Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.Annals of surgical oncology · 2024Article
- Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy.Prostate international · 2024Article
- Development of machine learning prognostic models for overall survival of prostate cancer patients with lymph node-positive.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathological lymph node involvement (pN1) after a pelvic lymph node dissection represents one of the most unfavorable prognostic factors for disease recurrence and cancer-specific mortality in prostate cancer. However, optimal management for pN1 patients remains unclear. Thus, the guideline from the European Association of Urology recommends discussing three following management options with pN1 patients after an extended pelvic lymph node dissection, based on nodal involvement characteristics: (i) offer adjuvant androgen-deprivation therapy, (ii) offer adjuvant androgen-deprivation therapy with additional radiotherapy and (iii) offer observation (expectant management) to a patient with ≤2 nodes and a prostate-specific antigen <0.1 ng/mL. Treatment intensification may reduce risks of recurrence and cancer-specific mortality, but it may increase adverse events and impair quality of life. Few randomized control trials for pN1 are under investigation. In addition, there are limited reports on the quality of life and patient-reported outcomes in patients with pN1. Therefore, more research is needed to establish an optimal therapeutic strategy for patients with pN1. This review summarizes current evidence on the treatments available for men with pN1, summarizes randomized control trials that included pN1 prostate cancer, and discusses future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.